CLAG-Based Induction Therapy in Previously Untreated High Risk Acute Myeloid Leukemia Patients

Highlights • 20 previously untreated AML patients were treated with CLAG based induction therapy. • The CR rate was 65% after one cycle and 80% after two cycles of therapy. • The mean duration of response is 36.8 months and the median overall survival is 29.0 months. • Patients with de novo AML had...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Leukemia research 2016-07, Vol.46, p.74-78
Hauptverfasser:	Seiter, Karen M.D, Ahmed, Nasir, Shaikh, Azfar, Baskind, Paul, Liu, Delong
Format:	Artikel
Sprache:	eng
Schlagworte:	Acute myeloid leukemia Adult Aged Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - therapeutic use Cladribine - administration & dosage CLAG Cytarabine - administration & dosage Granulocyte Colony-Stimulating Factor - administration & dosage Hematology, Oncology and Palliative Medicine Humans Induction Chemotherapy - methods Leukemia, Myeloid, Acute - drug therapy Leukemia, Myeloid, Acute - mortality Male Middle Aged Previously untreated Remission Induction Risk Secondary AML Survival Rate Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • 20 previously untreated AML patients were treated with CLAG based induction therapy. • The CR rate was 65% after one cycle and 80% after two cycles of therapy. • The mean duration of response is 36.8 months and the median overall survival is 29.0 months. • Patients with de novo AML had a 90.9% response to induction therapy and a median overall survival of 38.5 months.
ISSN:	0145-2126 1873-5835
DOI:	10.1016/j.leukres.2016.04.015